# Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients

> **NCT02018133** · — · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 8 (actual)

## Conditions studied

- CKD Stage 3/4

## Interventions

- **DRUG:** Vitamin D 2mg daily for 2 weeks oral paricalcitol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02018133
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02018133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02018133, "Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02018133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*